Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Eisai Announces Completion of Acquisition of Morphotek
May 1st, 2007
Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., today announces the completion of Eisai's acquisition of Morphotek(R), Inc. for US $325 million after excess net cash. The companies received notice that the 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 was terminated early by the Federal Trade Commission. Morphotek develops therapeutic monoclonal antibodies through the use of its proprietary human antibody technologies, Human MORPHODOMA(R) and Libradoma(TM). The company is leveraging these technologies to enrich its pipeline that currently includes therapeutic antibody leads for the...
Source: Cancer Weekly (2007-05-01)
|
